Should a PI-RADS 3 Lesion Be Biopsied?

PI-RADS 3 is the score radiologists assign when a prostate MRI finding is genuinely equivocal, and the biopsy question has no universal answer. A large meta-analysis puts the cancer detection rate for these lesions at roughly 20% when counting individual lesions and about 16% when counting per patient, which means the majority of PI-RADS 3 findings turn out to be benign or clinically insignificant. But that still leaves a meaningful minority harboring cancer that matters. The decision to biopsy hinges on a handful of clinical variables that can push an individual’s risk well above or below that average.

How Often PI-RADS 3 Lesions Turn Out To Be Cancer

The PI-RADS scoring system runs from 1 (almost certainly benign) to 5 (almost certainly cancer). A score of 3 means “equivocal,” and the numbers reflect that uncertainty. A systematic review and meta-analysis pooling data from multiple studies found cancer detection rates of about 20% at the lesion level and 16% at the patient level for PI-RADS 3. For comparison, PI-RADS 4 lesions harbor cancer roughly half the time, and PI-RADS 5 lesions roughly 85–89% of the time.¹ Those PI-RADS 3 numbers refer to any prostate cancer. When you narrow the question to clinically significant prostate cancer, the kind that would actually warrant treatment, estimates typically fall in the range of 10–30%.²

That wide range is not a rounding issue. It reflects real differences across study populations, MRI quality, and how aggressively the centers biopsy. Some institutions biopsy every PI-RADS 3 finding and catch more cancer; others apply filters and accept that some diagnoses will be delayed. Neither approach is clearly wrong, which is why these lesions have earned a reputation as the most debated category in prostate imaging.

PSA Density and Other Clinical Filters

PSA density, your PSA level divided by the volume of your prostate, is the clinical variable most commonly used to triage PI-RADS 3 findings. A larger prostate naturally produces more PSA, so a high PSA in a man with a small prostate is more worrisome than the same number in a man with a large gland. One study specifically examining PI-RADS 3 lesions found that PSA density was the strongest single predictor of both any prostate cancer and clinically significant cancer, outperforming age, PSA alone, and lesion size.³ Older age, higher PSA, larger lesion diameter, and smaller prostate volume were all individually associated with cancer in that analysis, but PSA density combined much of their predictive power into a single number.

The picture is not perfectly clean, though. A separate study looking specifically at men undergoing repeat biopsies found that PSA density strongly separated cancer risk among PI-RADS 4–5 lesions but showed almost no meaningful stratification in PI-RADS 3 lesions. In that population, the cancer detection rate in PI-RADS 3 lesions was about 16% with low PSA density and about 21% with high PSA density, a gap that was not statistically significant.⁴ That study’s context was repeat biopsy, which is a different clinical scenario than a first biopsy, but it is a reminder that no single variable sorts PI-RADS 3 lesions perfectly. A PSA density threshold of 0.15 is commonly used as a soft cutoff, but it should inform the decision rather than make it.

Where the Lesion Sits in the Prostate

The prostate has two main zones relevant to cancer risk: the peripheral zone, which wraps around the back of the gland and is where most cancers arise, and the transition zone, the inner tissue that tends to enlarge with age and cause urinary symptoms. A PI-RADS 3 lesion in the peripheral zone carries meaningfully higher cancer risk than one in the transition zone. Data from a comparative study found that the positive predictive value of a PI-RADS 3 finding for clinically significant cancer was roughly 10–18% in the peripheral zone but effectively 0–5% in the transition zone, depending on the biopsy technique.⁵

A multicenter study looking at quantitative MRI metrics confirmed this pattern. Peripheral zone location was an independent predictor of clinically significant cancer among PI-RADS 3 lesions, with over six times the odds compared to transition zone lesions after adjusting for other variables like prostate volume.⁶ The reason is partly biological and partly imaging-related: benign conditions like BPH nodules are common in the transition zone and can mimic suspicious findings on MRI, inflating the PI-RADS score for what turns out to be harmless tissue.⁷ Prostatitis and fibrosis can do the same thing. If your PI-RADS 3 lesion is in the transition zone, the odds that it is cancer are substantially lower than the overall average suggests.

Racial Disparities in PI-RADS 3 Cancer Rates

One of the more striking recent findings is that the cancer risk behind a PI-RADS 3 score varies dramatically by race. A secondary analysis of the PREVENT randomized trial found that Black men with PI-RADS 3 lesions had a clinically significant cancer rate of 60%, compared to 27% in White men. Black men were also younger at diagnosis and had higher PSA density. Asian men in the same study had a 0% rate of clinically significant cancer in PI-RADS 3 lesions, though the sample was small.⁸ Even after adjusting for age, biopsy approach, and PSA density, Black men with PI-RADS 3 or 4 lesions had higher odds of cancer detection than White men.

A separate study in a diverse cohort found that non-Hispanic Black men had nearly fivefold higher odds of clinically significant cancer on targeted biopsy of PI-RADS 3 lesions compared to non-Hispanic White and Hispanic men.⁹ These numbers are large enough to shift the biopsy decision. A PI-RADS 3 lesion in a Black man carries a baseline risk that looks more like a PI-RADS 4 in other populations. Most current guidelines do not explicitly account for race in the biopsy decision for PI-RADS 3 lesions, which means applying a uniform “watch and wait” strategy to all men could disproportionately delay diagnosis in the group at highest risk.

The Problem of Reader Disagreement

A practical concern that rarely comes up in the biopsy conversation is how reliably PI-RADS 3 gets assigned in the first place. The same MRI images shown to different radiologists frequently produce different scores. A single-center study had three radiologists with varying experience levels score the same set of prostate MRIs. The median agreement among all radiologist pairs for PI-RADS 3 was poor, with a kappa score of just 0.149, and the correlation between assigned PI-RADS scores and actual pathology results on biopsy was weak and not statistically significant.¹⁰ More experience did not reliably improve scoring accuracy.

Another study quantified the variability in terms of outcomes: the percentage of PI-RADS 3 lesions that turned out to be clinically insignificant ranged from 61% to 92% depending on which radiologist read the scan.¹¹ That is a huge swing. Some of the lesions one radiologist called a 3 would have been called a 2 or a 4 by another. If you are being told to biopsy based on a PI-RADS 3 score, it may be worth asking whether a second read was done, particularly if the MRI was interpreted at a center without a dedicated prostate MRI program. The quality of the scan itself also plays a role; image quality and diagnostic confidence can degrade with certain MRI technical parameters, and agreement between readers drops as scan quality decreases.¹¹

What Happens If You Defer the Biopsy

Choosing to monitor rather than biopsy a PI-RADS 3 lesion is a legitimate strategy, but it is not the same as doing nothing. Active surveillance data from a large cohort of men already diagnosed with low-grade prostate cancer offers a useful window into how PI-RADS 3 lesions behave over time. In that study, about 34% of men with PI-RADS 3 lesions on their initial MRI were eventually upgraded to a higher-grade cancer on subsequent biopsies, and 36% ultimately received treatment. By contrast, no patient whose MRI was negative (PI-RADS 1–2) required treatment. Among men whose MRI improved from PI-RADS 4–5 down to 3 on a follow-up scan, nearly half were still upgraded.¹²

Those numbers apply to men already known to have cancer, so they are not directly transferable to someone with a first-time PI-RADS 3 finding and no prior diagnosis. But they illustrate an important point: a PI-RADS 3 lesion that stays stable on imaging does not guarantee the underlying biology is equally stable. Men who choose surveillance typically repeat their MRI in 12 months and may incorporate PSA tracking in the interim. If the lesion grows, changes signal characteristics, or the PSA density climbs, the threshold for biopsy drops.

Biopsy Risks and Practical Tradeoffs

Prostate biopsy is not a zero-cost decision. The most common complications are minor bleeding, including blood in the urine and semen, which is nearly universal and self-limiting. About a quarter of men experience urinary symptoms afterward, though actual urinary retention is uncommon. Temporary erectile dysfunction occurs in a nontrivial fraction and typically resolves within one to six months. Infectious complications, while still relatively rare, have been increasing, particularly in men who are older or have other medical conditions.¹³

These risks tilt the calculus for PI-RADS 3 lesions specifically because the prior probability of finding actionable cancer is relatively low. Biopsying everyone with a PI-RADS 3 finding means subjecting roughly four out of five men to a procedure that finds either nothing or a low-grade cancer that may never need treatment. A cost-effectiveness analysis found that the optimal strategy was to biopsy men with PI-RADS 3 or higher and skip biopsy for those scoring below 3, which reduced total screening biopsies by about 15%.¹⁴ That analysis treated PI-RADS 3 as part of the “biopsy” group, but it did not account for the additional stratification now available through PSA density, lesion location, and demographics.

The biopsy technique matters too. One study of PI-RADS 3 lesions specifically found that if biopsies were skipped entirely, about 12% of clinically significant cancers would have been missed. MRI-targeted biopsies alone missed fewer (about 5%) while avoiding roughly a quarter of insignificant cancer diagnoses compared to a full template biopsy.¹⁵ Adding systematic cores on the same side as the lesion recovered most of that gap. If you do proceed with biopsy, targeted cores of the suspicious area combined with systematic sampling of the same side represent a reasonable middle ground between overtesting and underdetection.

Quantitative MRI Metrics That Could Help

Radiologists read MRI scans somewhat subjectively, which partly explains the reader disagreement discussed earlier. Researchers have been working on more objective, number-based approaches to sort PI-RADS 3 lesions. The apparent diffusion coefficient, a measurement extracted from a specific MRI sequence that reflects how freely water moves through tissue, is the most studied. Cancer cells are tightly packed, restricting water movement and lowering the ADC value. In the multicenter study mentioned earlier, the minimum ADC value within a lesion was an independent predictor of clinically significant cancer in PI-RADS 3 findings, with a diagnostic accuracy that was reasonably good.⁶

More complex approaches extract dozens or hundreds of mathematical features from MRI images, a technique called radiomics, and feed them into machine learning models. A multicenter study using features from multiple MRI sequences achieved an average diagnostic accuracy of about 0.80 for predicting clinically significant cancer in PI-RADS 3 lesions, and the model held up reasonably well when tested on data from an outside institution.¹⁶ Another study using features from a single MRI sequence achieved similar performance in a test set, and outperformed PSA density and prostate volume as standalone predictors.¹⁷ These tools are not yet in routine clinical use, but they represent a promising direction for turning an equivocal scan into a more confident recommendation.

Urine Biomarkers as a Tiebreaker

Another avenue for resolving PI-RADS 3 uncertainty is biological rather than imaging-based. Several urine biomarker panels are being studied as add-ons to MRI. One approach combines specific protein markers in urine with the PI-RADS score, and early results suggest that combining just two urinary biomarkers with the PI-RADS score could achieve high diagnostic accuracy, with an area under the curve of 0.89 for detecting prostate cancer.¹⁸ Adding the patient’s age to that model pushed accuracy even higher. A separate commercially available urine test, SelectMDx, showed scores that correlated positively with PI-RADS grade, with a statistically significant difference in test scores between PI-RADS 3 and PI-RADS 4 findings.¹⁹

The appeal of these tests for the PI-RADS 3 population is obvious: a urine sample carries zero procedural risk. If a biomarker panel could reliably push a man’s estimated risk below 5% or above 30%, it would simplify the biopsy decision in many cases. These tools remain investigational for this specific use, but several are commercially available and increasingly discussed at urology visits. Their main limitation right now is that the studies validating them in PI-RADS 3 populations are still relatively small.

Putting the Decision Together

No single factor determines whether a PI-RADS 3 lesion should be biopsied. In practice, the decision involves stacking several risk modifiers on top of the baseline 10–30% probability of clinically significant cancer. Factors that push toward biopsy include high PSA density, peripheral zone location, Black race, family history of prostate cancer, and a rising PSA trajectory. Factors that favor monitoring include low PSA density, transition zone location, small lesion size, large prostate volume, and the availability of follow-up MRI in 12 months. When three or four factors line up on one side, the choice becomes relatively clear. The genuinely difficult cases are the ones where the factors split.

If you are facing this decision, a few practical steps can help. First, confirm that your MRI was performed at a center experienced in prostate imaging and interpreted by a radiologist who reads a high volume of prostate MRIs. Reader variability is large enough that a second opinion on the imaging alone can change the score. Second, ask your urologist about your PSA density, not just your PSA. Third, discuss your race and family history explicitly; the data on racial disparities are strong enough that they should factor into the conversation, even though many guidelines have not caught up. And if you and your doctor agree on monitoring rather than immediate biopsy, commit to the follow-up plan rather than letting the finding drift out of view.

1
Prostate Cancer and Prostatic Diseases. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level
2
PubMed Central. To biopsy or not biopsy, that is the question – PI-RADS 3 prostate lesions – validation of clinical and radiological parameters for biopsy decision-making – Section: Introduction
3
PubMed Central. To biopsy or not biopsy, that is the question – PI-RADS 3 prostate lesions – validation of clinical and radiological parameters for biopsy decision-making – Section: Results
4
Prostate International. Risk stratification for repeat prostate biopsy: PI-RADS 3 lesions and the differential role of PSA density
5
NEAUA. Comparison Of The Incidence Of Clinically Significant Prostate Cancer In Patients With Isolated Peripheral Vs Transitional Zone PIRADS 3 Lesions
6
PubMed Central. The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions: a multicenter retrospective study – Section: Results
7
Applied Radiology. Review of Clinically Significant Cancer in Lesions Labeled PI-RADS 3 on MRI Using PI-RADS Version 2.1
8
PubMed Central. Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis – Section: Results
9
Urologic Oncology: Seminars and Original Investigations. Not all PI-RADS 3 lesions are the same: Higher rate of clinically significant prostate cancer among Black men on targeted biopsy in a diverse cohort
10
Abdominal Radiology. Evaluating the impact of reader experience on PI-RADS 3 of version 2.1 scoring concordance in multiparametric prostate MRI: a single-center analysis
11
PubMed Central. Accuracy, intra-, and inter-radiologist variability of PI-RADS v2.1 scoring for clinically significant prostate cancer detection – Section: Results
12
Prostate Cancer and Prostatic Diseases. Prognostic value of MR visibility/invisibility in men on Active Surveillance
13
European Urology. Complications After Systematic, Random, and Image-guided Prostate Biopsy
14
BJU International. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer
15
The French Journal of Urology. PI-RADS 3 MRI lesions: Are biopsies still necessary?
16
PubMed Central. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study
17
Journal of Magnetic Resonance Imaging. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions
18
Scientific Reports. Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy
19
PubMed. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection